Vaccine London, April 25, 2015 (Reuters/NAN) The world’s first malaria vaccine, produced by GlaxoSmithKline, could be approved by international regulators for use in Africa from October.
The final trial data showed that the shoe, called RTS, S offered partial protection for children for up to four years.
It will be the first licensed human vaccine against a parasitic disease, and could help prevent millions of cases of malaria, which currently kills more than 600,000 people a year.
